CAJ | 학술논문

目的：检测转移相关基因（ MTA1）蛋白在小细胞肺癌（ SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测例无远处转移SCLC组织标本中MTA1的表达，根据免疫组化结果分为两类：低表达（≤6分）和高表达（＞6分）；分析MTA1表达水平与临床病理特征、EP方案（足叶乙甙mg/m2静滴，d1～d5；顺铂mg/m2静滴，d1，3周为周期，共～6个周期）化疗疗效及预后的关系。结果例SCLC组织中MTA1高表达率为.2％（37/52），18例癌旁组织均为低表达（100.0％）；MTA1表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义（ P＜0.05），而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义（ P＞0.05）；MTA1高表达组的EP方案化疗敏感率低于MTA1低表达组（54.1％ vs．80.0％，P＝0.020）；MTA1低表达组的中位无进展生存期和总生存期均优于MTA1高表达组（20个月vs．8个月，33个月vs．18个月），差异有统计学意义（P＜0.05）。结论MTA1在SCLC组织中高表达，且与肿瘤转移、耐药及预后密切相关。
목적：검측전이상관기인（ MTA1）단백재소세포폐암（ SCLC）조직중적표체정황，탐토기재SCLC전이、예후화화료민감성예측중적작용。방법채용면역조직화학법검측례무원처전이SCLC조직표본중MTA1적표체，근거면역조화결과분위량류：저표체（≤6분）화고표체（＞6분）；분석MTA1표체수평여림상병리특정、EP방안（족협을대mg/m2정적，d1～d5；순박mg/m2정적，d1，3주위주기，공～6개주기）화료료효급예후적관계。결과례SCLC조직중MTA1고표체솔위.2％（37/52），18례암방조직균위저표체（100.0％）；MTA1표체재불동종류직경、TNM분기、림파결전이여부화유무맥관침범지간적차이유통계학의의（ P＜0.05），이재성별、년령、VALG분기급종류부위지간적차이무통계학의의（ P＞0.05）；MTA1고표체조적EP방안화료민감솔저우MTA1저표체조（54.1％ vs．80.0％，P＝0.020）；MTA1저표체조적중위무진전생존기화총생존기균우우MTA1고표체조（20개월vs．8개월，33개월vs．18개월），차이유통계학의의（P＜0.05）。결론MTA1재SCLC조직중고표체，차여종류전이、내약급예후밀절상관。
Objective To detect the expression of metastasis-associated-gene 1( MTA1) protein in tissues of small cell lung cancer( SCLC ) and explore the role of MTA1 in metastasis, prognosis and chemotherapy sensitivity of SCLC. Methods The expression of MTA1 was detected in 52 non-distal metastatic SCLC tissues by immunohistochemical staining. The results were divided into low-level expression(≤6) and high-level expression(>6) according to the immunohistochemical staining counting method. The re-lationships between expression of MTA1 and clinicopathological characteristics, efficacy of EP regimen( etoposide 100mg/m2 iv, d1-d5;cisplatin 60mg/m2 iv d1;3-week cycle for 4-6 cycles) and prognosis were investigated. Results Thirty-seven SCLC tissues were found of high-level MTA1 expression( 71.2%) , while MTA1 was expressed at a low-level in all 18 adjacent tissues. There were significant correlations between the expression of MTA1 and tumor size, TNM stage, lymph node metastasis and vascular invasion( P<0.05) . No significant correlation existed between the expression of MTA1 and gender, age, VALG stage and tumor sites( P>0.05) . The low-level expression group was more sensitive to EP chemotherapy than the high-level expression group( 80.0% vs. 54.1%, P=0.020) . The me-dian progression-free survival and overall survival of the low-level expression group were superior to those of the high-level expression group(20 months vs. 8 months, 33 months vs. 18 months) with statistical significance(P<0.05). Conclusion MTA1 is highly ex-pressed in SCLC tissue, and is closely correlated with tumor metastasis, drug resistance and prognosis.